Merger – Talk Bio

Y-mAbs Therapeutics Acquired by SERB Pharmaceuticals in $412 Million Buyout Following Strategic Review

1 month ago talkbio0Tagged all-cash tender, Danyelza, Infrequent, Merger, Neoplasms, pharmaceutical acquisition, Serbs, strategic review, Y-mAbs

Y-mAbs Therapeutics; SERB Pharmaceuticals; buyout; Danyelza; rare oncology; merger; pharmaceutical acquisition; strategic review; all-cash tender offer

BioNTech Acquires CureVac to Advance mRNA Cancer Therapies and End Patent Disputes

3 months ago talkbio0Tagged Acquisition, BioNTech, biotech merger, COVID19 (disease), CureVac, Immunotherapy for cancer, Legal patent, Merger, RNA, Messenger, Vaccines

BioNTech; CureVac; mRNA; acquisition; COVID-19 vaccine; cancer immunotherapy; merger; patent dispute; biotech merger

Bluebird Private Equity Buyout Boosts Upfront Cash for Shareholders

4 months ago talkbio0Tagged Capital, Carlyle, contingent value right, CVR, DKK1 gene, Family Turdidae (organism), Merger, Private Equity, shareholders, upfront cash

Bluebird; private equity buyout; shareholders; upfront cash; Carlyle; SK Capital; contingent value right; CVR; buyout terms; merger

Acelyrin Rebuffs Concentra’s Acquisition Bid, Reaffirms Commitment to Alumis Merger

6 months ago talkbio0Tagged Acelyrin, Acquisition, all-stock, Alumis, Biological Factors, Concentra Biosciences, Immunology, Merger, Transaction

Acelyrin, Concentra Biosciences, Alumis, Merger, Acquisition offer, Immunology, Biopharmaceuticals, All-stock transaction

BridgeBio Oncology Therapeutics Goes Public via $450M SPAC Merger

6 months ago talkbio0Tagged Biochemical Pathway, BridgeBio, cancer pipeline, Helix (Snails), inhibitors, K-ras Oncogene, KRAS, Merger, Neoplasms, PI3 K pathway, ras Oncogene, SPAC

BridgeBio, oncology, SPAC merger, Helix Acquisition Corp. II, KRAS inhibitors, cancer pipeline, RAS pathway, PI3K pathway

Concentra’s Surprise Bid Disrupts Acelyrin-Alumis Merger Plans

7 months ago talkbio0Tagged Acelyrin, Alumis, biopharmaceutical industry, Concentra Biosciences, Disruption, M&A, Merger, Unsolicited Adverse Event

Concentra Biosciences, Acelyrin, Alumis, merger disruption, unsolicited offer, biopharmaceutical industry, M&A

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Advance Development of Atopic Dermatitis Treatment

9 months ago talkbio0Tagged Biological Factors, Clinical stage finding, Dermatitis, Atopic, Ikena Oncology, IMG-007, Implantation procedure, Inmagene Biopharmaceuticals, Merger, Monoclonal Antibodies, Private Room, TNFRSF4 gene

Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Atopic Dermatitis, IMG-007, Monoclonal Antibody, OX40, Biopharmaceuticals, Clinical Stage, Private Placement